Ads
related to: alternative drug for ezetimibe 5- Co-Pay Program
Resources
to Support Your Patients
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Resources
More Information
For Your Practice
- Patient Identification
View a Patient Profile
to Learn More
- Request Samples
Get patients started
with a 14-day sample
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Co-Pay Program
nexlizet.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic medication. [5] In 2022, it was the 79th most commonly prescribed medication in the United States, with more than 8 million prescriptions. [11] [12]
In February 2020, bempedoic acid was approved for use in the United States both as a standalone drug (brand name Nexletol) [5] [17] [18] [19] and in a fixed-dose combination with ezetimibe (brand name Nexlizet). [20] The U.S. Food and Drug Administration (FDA) granted the approval of Nexletol to Esperion Therapeutics. [2] [5]
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [1] [3] It is a combination of bempedoic acid and ezetimibe. [1] [2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. [2]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
The drug, suzetrigine, received the FDA's official stamp of approval Thursday to be sold as a 50-milligram prescription pill taken every 12 hours, according to a press release.
In a randomized study it showed a LDL-C reduction of 63.6 percent, significantly more than bempedoic acid/ezetimibe, and it may also be more effective than bempedoic acid / statin combination therapy.
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
Ads
related to: alternative drug for ezetimibe 5nexlizet.com has been visited by 100K+ users in the past month